tirzepatide dose chart Chart: 2.5 to 15 mg Schedule switching from semaglutide to tirzepatide

We bill your health insurance and there is no cost to you

People with diabetes or insulin resistance Tirzepatide was originally developed for type 2 diabetes (Mounjaro) before being approved for weight management (Zepbound)

Individuals with a history of pancreatitis should avoid using Tirzepatide

The GLP-1RA with better outcomes in clinical trials is semaglutide since this drug can reduce up to 15% of the baseline weight after a 2.4 mg subcutaneous weekly dose

**Nausea and Vomiting**: These are the most common side effects, especially when starting the medication or increasing the dose

Transitioning from semaglutide to tirzepatide is straightforward with proper guidance